Mouse IgG₁ Isotype Control [Clone HKSP84] — Purified in vivo GOLD™ Functional Grade

Clone HKSP84 is a Mouse IgG1 isotype control antibody commonly used in in vivo mouse studies. Its primary application is as a negative control to ensure that any observed effects in experiments are due to the specific antibody being tested rather than non-specific binding. Here are some common in vivo applications of clone HKSP84:

1. Immunological Research: HKSP84 is used to validate the specificity of primary antibodies in various immunological assays, helping researchers distinguish between specific and non-specific interactions.

2. In Vivo Studies: This clone is particularly suitable for in vivo studies due to its low endotoxin levels, which are crucial for minimizing unwanted inflammatory responses during experiments.

3. Benchmarking Non-Specific Binding: By using HKSP84 as a control, researchers can assess the background signal in assays like ELISA, flow cytometry, and immunohistochemistry, ensuring that the results are accurate and reliable.

4. Preclinical Research: It supports preclinical research by providing a reliable control for experiments involving mouse monoclonal antibodies, helping to establish the efficacy and safety of therapeutic antibodies.

HKSP84 is most commonly used as a mouse IgG1 isotype control antibody in immunological studies, serving as a negative control alongside other primary antibodies to validate specificity.

Other commonly used antibodies or proteins paired with, or tested alongside, HKSP84 in the literature include:

• Cell surface marker antibodies: Frequently, HKSP84 is used in flow cytometry or immunophenotyping panels together with antibodies targeting cell markers such as:
  • CD3, CD4, CD8 (T cell markers)
  • CD11b, F4/80 (myeloid cell markers)
  • CD14, HLA-DR, CD19, CD33, CD45, CD1c, NKp46, TER119 (various immune cell subsets).
• Antibodies against signaling proteins, transcription factors, or cytokines, for example:
  • IFN-γ, IFNAR1, TNF-α.
• Therapeutic or experimental antibodies: For experimental validation or in combination studies, HKSP84 can be paired with biologicals such as:
  • Rituximab (an anti-CD20 antibody)
  • Anti-CD47, anti-SIRPα (immune checkpoint blockade agents).
• Secondary antibodies and detection reagents: Various labeled secondary antibodies (e.g., Alexa Fluor, HRP, biotin-streptavidin systems) are commonly used for signal detection in assays where HKSP84 is utilized as a control.

In summary, HKSP84 is rarely used in isolation; it is typically included to benchmark specificity against background, in multiplexed experiments investigating immune phenotypes, signaling activity, or cell sorting where a broad array of immune marker antibodies are used simultaneously.

There is limited specific information available in the search results about the key findings from clone HKSP84 citations in scientific literature. Clone HKSP84 is primarily known as a Mouse IgG1 Isotype Control, commonly used for in vivo and immunological research. It is often cited for its minimal cross-reactivity with various species' cells and tissues, making it a useful negative control in experiments.

However, there is no detailed analysis or compilation of scientific findings specifically linked to clone HKSP84 in the provided search results. Instead, the discussions focus on its characteristics and applications as an isotype control rather than highlighting specific research outcomes. For detailed scientific findings involving clone HKSP84, a more comprehensive literature review would be necessary.

In general, isotype controls like HKSP84 are essential in scientific research for ensuring that results are accurate by minimizing background interactions, but they are not typically the focus of specific "key findings" in studies. Their role is more supportive, ensuring that the results are not skewed by non-specific binding.

Dosing Regimens for Clone HKSP84 in Mouse Models

Data Availability

There is no peer-reviewed, published research directly detailing the specific dosing regimens of mouse IgG1 isotype control clone HKSP84 across different mouse models in the provided search results. No primary literature or preclinical studies were identified that explicitly describe dose optimization, pharmacokinetics (PK), or pharmacodynamics (PD) for HKSP84 in various disease or immunological contexts.

Manufacturer Guidance

Product descriptions and vendor websites (e.g., Leinco Technologies) note that dosing may vary depending on factors such as mouse strain, disease model (e.g., tumor type, infection, autoimmunity), and the desired immunological effect. However, these sources do not provide specific dose ranges, schedules, or comparative data across different models. Instead, they emphasize that optimal dosing should be determined empirically for each experimental context.

General Principles for Isotype Control Antibodies in Mice

While specific data on HKSP84 are lacking, general practices for isotype control antibodies in mouse models can be inferred:

• Standard Dosing: Many in vivo studies with murine monoclonal antibodies (including isotype controls) typically use doses in the range of 100–500 μg per mouse (approximately 5–25 mg/kg, assuming a 20 g mouse), administered intravenously or intraperitoneally.
• Frequency: Dosing frequency is often once or twice weekly, but this can vary based on the experimental design and the antibody’s half-life in the specific model.
• Empirical Optimization: Actual dosing for HKSP84 should be empirically determined for each model, as factors such as target engagement (if any), mouse strain, immune status, and disease context can influence both efficacy and toxicity.
• Controls: Isotype controls like HKSP84 are generally used at the same dose and schedule as the experimental therapeutic antibody to ensure that any observed effects are due to the specific targeting and not to non-specific IgG effects.

Summary Table

Key Takeaways

• No published data specifically address HKSP84 dosing across different mouse models.
• Dosing is expected to vary by model and should be determined empirically.
• General in vivo antibody dosing guidelines (e.g., 5–25 mg/kg, weekly) may serve as a starting point, but optimization is essential.
• Always match the isotype control dose and schedule to the experimental antibody to ensure valid comparisons.

For precise dosing, consult the antibody provider’s recommendations and conduct pilot experiments in your specific mouse model to establish the optimal regimen.